Mealey's (January 15, 2020, 1:33 PM EST) -- WASHINGTON, D.C. — An August finding by the Federal Circuit U.S. Court of Appeals that it lacks jurisdiction over allegations that the Patent Trial and Appeal Board violated SAS Institute, Inc. v. Iancu when, on remand, it issued a discretionary denial of three petitions for inter partes review (IPR) will stand, the Federal Circuit announced Jan. 13 (BioDelivery Sciences International Inc. v. Aquestive Therapeutics Inc., Nos. 2019-1643, -1644, -1645, Fed. Cir., 2020 U.S. App. LEXIS 1030)....